血浆D-二聚体是指导再植入时机的有前景标志物:一项前瞻性队列研究
该前瞻性队列研究纳入136例接受再植入关节成形术的患者,最终分析114例,评估血浆D-二聚体及其他血清学标志物预测再植入术后感染控制成功的诊断效用。中位随访3.2年,33例(28.9%)治疗失败,失败组血浆D-二聚体中位数显著高于成功组(1604 vs 631 ng/mL,P < .001),而CRP、ESR和纤维蛋白原在两组间无显著差异。血浆D-二聚体诊断效用最佳(AUC 0.724),优于ESR、CRP和纤维蛋白原。
要点
- 再植入术前血浆D-二聚体中位数失败组1604 ng/mL vs 成功组631 ng/mL,P < .001。
- 血浆D-二聚体AUC 0.724,优于ESR(0.565)、CRP(0.541)和纤维蛋白原(0.485)。
- 血浆D-二聚体≥1604 ng/mL为预测再植入术后失败的最佳截断值。
核心结论
- 血浆D-二聚体在预测两阶段交换关节成形术第二阶段再植入术后失败方面优于血清ESR、CRP和纤维蛋白原。
- 基于该前瞻性研究结果,血浆D-二聚体可能是评估再植入手术患者感染控制情况的有前景标志物。
研究设计与样本
- 前瞻性队列研究,纳入2016年11月至2020年12月期间接受再植入关节成形术的136例患者,最终分析114例。
- 应用严格纳入标准,包括再植入术前需进行为期两周的「抗生素假期」。
- 术前测量血浆D-二聚体、红细胞沉降率(ESR)、C反应蛋白(CRP)和纤维蛋白原。
- 治疗成功采用肌肉骨骼感染学会结局报告工具定义。
- 采用受试者工作特征曲线评估各生物标志物预测再植入术后失败(至少随访1年)的预后准确性。
主要发现
- 平均随访3.2年(范围1.0至5.7年)时,33例患者(28.9%)发生治疗失败。
- 治疗失败组血浆D-二聚体中位数为1604 ng/mL,成功组为631 ng/mL,失败组显著高于成功组(P < .001)。
- 中位CRP、ESR和纤维蛋白原在成功组与失败组之间无显著差异。
- 血浆D-二聚体诊断效用最佳:AUC 0.724,敏感性51.5%,特异性92.6%。
- ESR:AUC 0.565,敏感性93.3%,特异性22.5%;CRP:AUC 0.541,敏感性87.5%,特异性26.3%;纤维蛋白原:AUC 0.485,敏感性30.4%,特异性80.0%。
关键数值与推荐
- 治疗成功采用肌肉骨骼感染学会结局报告工具定义。
- 血浆D-二聚体≥1604 ng/mL为预测再植入术后失败的最佳截断值,AUC 0.724,敏感性51.5%,特异性92.6%。
- ESR AUC 0.565,敏感性93.3%,特异性22.5%;CRP AUC 0.541,敏感性87.5%,特异性26.3%;纤维蛋白原AUC 0.485,敏感性30.4%,特异性80.0%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two-stage exchange arthroplasty remains the preferred surgical treatment for chronic periprosthetic joint infection. Currently, there is no single reliable marker to determine the optimal timing for reimplantation. The purpose of this prospective study was to assess the diagnostic utility of plasma D-dimer and other serological markers in predicting successful control of infection following reimplantation. METHODS: This study enrolled 136 patients undergoing reimplantation arthroplasty between November 2016 and December 2020. Strict inclusion criteria were applied including the need for a two-week "antibiotic holiday" prior to reimplantation. A total of 114 patients were included in the final analysis. Plasma D-dimer, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fibrinogen were measured preoperatively. Treatment success was defined using the Musculoskeletal Infection Society Outcome-Reporting Tool. Receiver operating characteristic curves were used to assess the prognostic accuracy of each biomarker in predicting failure following reimplantation at a minimum 1-year follow-up. RESULTS: Treatment failure occurred in 33 patients (28.9%) at a mean follow-up of 3.2 years (range, 1.0 to 5.7). Median plasma D-dimer was significantly higher in the treatment failure group (1,604 versus 631 ng/mL, P < .001), whereas median CRP, ESR, and fibrinogen were not significantly different between the success and failure groups. Plasma D-dimer demonstrated the best diagnostic utility (area under the curve [AUC] 0.724, sensitivity 51.5%, specificity 92.6%), outperforming ESR (AUC 0.565, sensitivity 93.3%, specificity 22.5%), CRP (AUC 0.541, sensitivity 87.5%, specificity 26.3%), and fibrinogen (AUC 0.485, sensitivity 30.4%, specificity 80.0%). Plasma D-dimer level of ≥1,604 ng/mL was identified as the optimal cutoff that predicted failure following reimplantation. CONCLUSION: Plasma D-dimer was superior to serum ESR, CRP, and fibrinogen in predicting failure after the second stage of a two-stage exchange arthroplasty for periprosthetic joint infection. Based on the findings of this prospective study, plasma D-dimer may be a promising marker in assessing the control of infection in patients undergoing reimplantation surgery. LEVEL OF EVIDENCE: Level II.
引用
- Tarabichi S, Goh GS, Fernández-Rodríguez D, et al. Plasma D-Dimer Is a Promising Marker to Guide Timing of Reimplantation: A Prospective Cohort Study. J Arthroplasty. 2023. PMID: 37172794. doi:10.1016/j.arth.2023.04.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。